Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATACAND vs BYVALSON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
Treatment of hypertension,Treatment of heart failure (NYHA class II-IV and left ventricular systolic dysfunction) to reduce cardiovascular death and hospitalization for heart failure
FDA-approved for the treatment of hypertension, heart failure (NYHA class II-IV), and to reduce cardiovascular mortality in stable post-myocardial infarction patients with left ventricular dysfunction or failure.,Off-label uses include diabetic nephropathy, prevention of atrial fibrillation recurrence, and migraine prophylaxis.
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
160 mg orally once daily.
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Candesartan is primarily metabolized by ester hydrolysis to its active metabolite, candesartan, and further undergoes O-deethylation by CYP2C9 (minor route).
Valsartan is primarily metabolized by CYP2C9 and minimally by CYP3A4. It undergoes glucuronidation via UGT1A3, UGT1A9, and UGT2B7. The major metabolite is inactive.
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
High protein binding: >99%, primarily to serum albumin.
95% bound primarily to albumin
Volume of distribution (Vd) is approximately 0.13 L/kg (mean 9 L). This low Vd indicates limited extravascular distribution, consistent with high plasma protein binding.
Vd 8-10 L/kg; suggests extensive extravascular distribution
Absolute oral bioavailability is approximately 15% (prodrug candesartan cilexetil is completely converted to active candesartan during absorption). Food does not affect bioavailability.
Oral: 50% (range 40-60%); food reduces peak concentration but not AUC
No initial dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min (including dialysis), initiate at 4 mg once daily and titrate cautiously with monitoring.
No dosage adjustment required for GFR ≥30 m L/min; not recommended for GFR <30 m L/min.
For Child-Pugh Class A or B: initiate at 4 mg once daily and titrate cautiously. Child-Pugh Class C: not recommended (no data).
Contraindicated in severe hepatic impairment (Child-Pugh class C); no adjustment for mild to moderate impairment (Child-Pugh A or B).
For children ≥1 year and <6 years: 0.2-0.4 mg/kg/day once daily or divided twice daily; maximum 0.6 mg/kg/day (up to 32 mg/day). For children ≥6 years: 4-8 mg once initially; may increase to 16 mg once daily (or 32 mg daily in larger children).
Safety and efficacy not established in pediatric patients.
Start at 4 mg once daily in patients ≥75 years; adjust based on blood pressure response and renal function (e.g., GFR <30 m L/min).
No specific dose adjustment recommended; initiate cautiously due to potential for decreased renal function.
When pregnancy is detected, discontinue ATACAND as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal malformations, oligohydramnios, and neonatal renal failure. Discontinue as soon as pregnancy is detected.
Hypotension: Symptomatic hypotension may occur in volume-depleted patients or those with heart failure.,Hyperkalemia: Monitor serum potassium, especially in patients with renal impairment or on potassium-sparing diuretics.,Renal impairment: Use caution in patients with renal artery stenosis or severe renal impairment; monitor renal function.,Fetal/neonatal morbidity and mortality: As noted in black box warning.,Avoid use in patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney.
Hypotension in volume- or salt-depleted patients,Hyperkalemia, especially with renal impairment, diabetes, or concomitant potassium-sparing diuretics,Renal function impairment, including acute renal failure,Angioedema (rare),Use caution in severe aortic stenosis,Avoid concomitant use with aliskiren in diabetic patients
Hypersensitivity to candesartan or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
Pregnancy (absolute),History of angioedema from any ARB or ACE inhibitor,Concomitant use with aliskiren in diabetic patients (absolute),Severe hepatic impairment (Child-Pugh class C) (relative)
No significant food interactions. Avoid potassium-rich foods (e.g., bananas, oranges, spinach, avocados) in large amounts if also taking potassium supplements or potassium-sparing diuretics. Salt substitutes containing potassium chloride should be used cautiously.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium chloride, as BYVALSON can increase potassium levels.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects, hypotension, anuria) due to direct renin-angiotensin system blockade. Risk of neonatal renal failure and hypotension if exposed after 20 weeks gestation.
Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypotension. Risk is highest in the second and third trimesters; first-trimester exposure may also increase risk of congenital malformations.
No data on candesartan in human milk; animal studies detect drug in milk. M/P ratio unknown. Avoid breastfeeding due to potential risk of neonatal hypotension and renal impairment.
No data on Byvalson (valsartan/nebivolol) in breast milk. Valsartan is excreted in rat milk; unknown in humans. Nebivolol is likely excreted in human milk. Due to potential for adverse effects in nursing infants (hypotension, bradycardia), breastfeeding is not recommended. M/P ratio not established.
Avoid use in second and third trimesters due to fetotoxicity. If inadvertent exposure occurs, discontinue drug immediately. No dose adjustment recommended for first trimester use, but consider alternative antihypertensive agent throughout pregnancy.
Byvalson is contraindicated in pregnancy; no dose adjustment is recommended. Alternative antihypertensives with established safety profiles should be used. If exposure occurs, discontinue immediately and manage with appropriate therapy.
ATACAND (candesartan cilexetil) is an angiotensin II receptor blocker (ARB) used primarily for hypertension and heart failure. Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation or dose adjustment. Avoid use in pregnancy (Category D). May cause angioedema; discontinue immediately if occurs. Dual blockade with ACE inhibitors or aliskiren increases risk of hypotension, hyperkalemia, and renal impairment.
BYVALSON (sacubitril/valsartan) is a first-in-class ARNI approved for heart failure with reduced ejection fraction (HFr EF). Monitor blood pressure and renal function closely upon initiation, especially in patients on high-dose ACE inhibitors or ARBs. Avoid use with ACE inhibitors within 36 hours due to risk of angioedema. May cause hypotension, hyperkalemia, and renal impairment. Titrate every 2-4 weeks to target dose of 97/103 mg BID as tolerated.
Take ATACAND exactly as prescribed, typically once daily with or without food.,Do not use if pregnant or planning pregnancy; consult doctor immediately if pregnancy occurs.,May cause dizziness or lightheadedness, especially during initial therapy; avoid driving until effects are known.,Avoid potassium supplements or salt substitutes containing potassium unless directed by healthcare provider.,Report signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to physician immediately.,Maintain adequate hydration and avoid dehydration (excessive sweating, vomiting, diarrhea).
Do not take within 36 hours of any ACE inhibitor medication.,Take BYVALSON twice daily with or without food.,Monitor blood pressure regularly; report dizziness or fainting.,Avoid salt substitutes containing potassium.,Seek medical help immediately if you experience swelling of the face, lips, or throat.,Stay hydrated but do not use potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATACAND vs BYVALSON, answered by our medical review team.
ATACAND is a Angiotensin II Receptor Blocker that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. BYVALSON is a Angiotensin II Receptor Blocker that works by Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATACAND and BYVALSON depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATACAND is: Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.. The standard adult dose of BYVALSON is: 160 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATACAND and BYVALSON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATACAND is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, sk. BYVALSON is classified as Category C. Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypoten. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.